Advertisement

Topics

Selumetinib Granted Orphan Drug Designation by the U.S. FDA for Neurofibromatosis Type 1

06:30 EST 15 Feb 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
AstraZeneca and Merck (NYSE:MRK), known as MSD outside the U.S. and Canada, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for selumetinib, a MEK 1/2 inhibitor, for the...

Other Sources for this Article

Merck
Media:
Pamela Eisele, 267-305-3558
Courtney Ronaldo, 908-442-5695
or
Investors
Teri Loxam, 908-740-1986
Michael DeCarbo, 908-740-1807

NEXT ARTICLE

More From BioPortfolio on "Selumetinib Granted Orphan Drug Designation by the U.S. FDA for Neurofibromatosis Type 1"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Merck and Co
Merck & Co is the 7th largest pharmaceutical company in the world based on annual sales, which reached $25,236m in 2009. They have developed 14 vaccines and over 40 prescription products in the major therapeutic areas of cardiovascular disease, respi...